Table 2. High output cardiac failure group summarized data.
Baseline | 3 ms | 6 ms | 12 ms | 18 ms | 24 ms | Comments | ||
Pt 1: F 47 y/o. | CI | 5.6 | 6.3 | 4.3 | 4.3 | Re-induction after 3 years (bleeding). Died due to a septic shock almost 4 years after enrollment while on LT list | ||
Co | 8.6 | 9.2 | 6.7 | 6.7 | ||||
PSP | 53 | 44 | 35 | |||||
Hb | 9.1 | 12.1 | 9.3 | 9.8 | 7 | |||
Bvz | 6 | 2 | ||||||
Baseline | 3 ms | 6 ms | 12 ms | 18 ms | 24 ms | Comments | ||
Pt 2: F 53 y/o. | CI | 4.5 | 4 | Died due to pneumonia about 20 months after enrollment | ||||
Co | 7.5 | 6.2 | ||||||
PSP | 45 | 60 | 28 | 45 | ||||
Hb | 12.4 | 13.5 | 12.8 | 12.5 | ||||
Bvz | 6 | |||||||
Baseline | 3 ms | 6 ms | 12 ms | 18 ms | 24 ms | Comments | ||
Pt 3: F 36 y/o. | CI | 6.2 | 3.1 | 3.1 | 4.9 | LT 2 years after enrollment. Alive | ||
Co | 9.3 | 4.6 | 4.1 | 7.7 | ||||
PSP | 36 | 24 | 22 | |||||
Hb | 7 | 8.7 | 7.5 | 7.6 | ||||
Bvz | 6 | 3 | ||||||
Baseline | 3 ms | 6 ms | 12 ms | 18 ms | 24 ms | Comments | ||
Pt 4: M 45 y/o | CI | 4.1 | 3.4 | 5.6 | LT 1 year after enrollment. Alive | |||
Co | 8 | 6.3 | 10 | |||||
PSP | 65 | 79 | 121 | 62 | ||||
Hb | 9.3 | 10.7 | 10.6 | 8.4 | 8.5 | 9.3 | ||
Bvz | 6 | |||||||
Baseline | 3 ms | 6 ms | 12 ms | 18 ms | 24 ms | Comments | ||
Pt 5: F 81 y/o. | CI | Died due to cardiogenic shock about 4 days after receiving first dose of bevacizumab | ||||||
Co | ||||||||
PSP | 72 | |||||||
Hb | 10.4 | |||||||
Bvz | 1 | |||||||
Baseline | 3 ms | 6 ms | 12 ms | 18 ms | 24 ms | Comments | ||
Pt 6: M 72 y/o | CI | 4.5 | Died due to pneumonia after receiving 2 doses of bevacizumab | |||||
Co | 9.2 | |||||||
PSP | 71 | |||||||
Hb | 8 | |||||||
Bvz | 2 | |||||||
Baseline | 3 ms | 6 ms | 12 ms | 18 ms | 24 ms | Comments | ||
Pt 7: M 61 y/o | CI | 3.8 | Alive, recently enrolled | |||||
Co | 6.7 | |||||||
PSP | 65 | |||||||
Hb | 8.4 | |||||||
Bvz | 1 |
Pt: patient. M: male. F: female. CI: cardiac index L/m2/min. Co: cardiac output L/min. PSP: pulmonary systolic pressure mmHg. Hb: hemoglobin g/dl. Bvz: number of bevacizumab applications. LT: Liver transplantation.